Series B round brings $21mm to Kleo
Kleo Pharmaceuticals Inc. (immuno-oncology) raised $21mm through an oversubscribed Series B round led by PeptiDream (development partner under a 2017 deal) and including Biohaven Pharmaceuticals. The company is developing cancer therapies based on its Antibody Recruiting Molecules (ARM) technology, and will use the Series B funds to advance its first candidates into human studies.
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com